Clinical data of Medigene's dendritic cell (DC) vaccines in AML presented at CIMT conference
(Thomson Reuters ONE) -
Medigene AG /
Clinical data of Medigene's dendritic cell (DC) vaccines in AML presented at
CIMT conference
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 11 May 2016. Medigene AG (MDG1, Frankfurt, Prime Standard),
a clinical stage immune-oncology company focusing on the development of T cell
immunotherapies for the treatment of cancer, informs that the academic group of
Prof. Gunnar Kvalheim at the Department of Cellular Therapy at the Oslo
University Hospital, Norway, has presented clinical data on Compassionate Use[1]
patients receiving dendritic cell (DC) vaccines for the treatment of acute
myeloid leukaemia (AML) utilizing Medigene's DC vaccine technology at the
14(th) Cancer Immunotherapy Conference (CIMT) in Mainz, Germany. CIMT is
Europe's largest meeting focused on cancer immunotherapy research and
development.
The poster presentation of the Oslo University Hospital showed preliminary data
from five AML patients receiving DC vaccines targeting the antigens Wilm's
tumor-1 (WT-1) and preferentially expressed antigen in melanoma (PRAME)
employing Medigene's new generation monocyte-derived fast dendritic cells. The
poster is entitled "WT-1 and PRAME mRNA transfected TLR 7/8 polarized fast DCs
vaccines in AML patients raise specific immune responses that correlate with
clinical outcome".
AML is frequently diagnosed in elderly patients, who normally cannot tolerate
intensive chemotherapy and/or stem cell transplantation, making curative
treatment difficult and rates of early relapse high.
Results reported here are from five patients, where DC vaccination was started
after hematopoietic recovery from first line chemotherapy treatment.
Data from the first four patients has already been reported at the 57th Annual
Meeting of the American Society of Hematology (ASH) in December 2015. Those four
patients have now been treated between 16 and 26 months.
Prof. Gunnar Kvalheim, Head of Department of Cellular Therapy, Oslo University
Hospital, explains: "Altogether, these results show that fast TLR- polarized DCs
can induce or enhance specific T cell responses with a patient individual
pattern. Clinical responses are related to immune responses and can result in
prolonged survival in AML patients not eligible for curative treatment."
Prof. Dolores J. Schendel, CEO and CSO of Medigene AG, adds: "These positive
results encourage us in pursuing our proprietary DC vaccine development program
for which we are currently conducting our own Phase I/II clinical AML trial,
expanding the ongoing academic clinical studies."
The Oslo University Hospital has an agreement with Medigene for the use of
Medigene`s new generation DC vaccines for their ongoing academic clinical
studies. Medigene's DC vaccines are produced according to GMP guidelines at the
Department of Cellular Therapy at the Oslo University Hospital. Acute myeloid
leukaemia is Medigene's lead indication in its DC vaccine program.
About Medigene's DC vaccines: The platform for the development of antigen-
tailored DC vaccines is the most advanced platform of the highly innovative and
complementary immunotherapy platforms of Medigene Immunotherapies. Currently,
Medigene evaluates its DC vaccines in a company-sponsored Phase I/II clinical
trial in acute myeloid leukaemia (AML). Further studies utilizing Medigene's DC
vaccine technology include two ongoing clinical investigator-initiated trials
(IITs): a clinical Phase I/II trial for treating acute myeloid leukaemia (AML)
at Ludwig Maximilians University Hospital Grosshadern, Munich, and a clinical
Phase II trial of a treatment for prostate cancer at Oslo University Hospital.
Moreover, compassionate use patients are treated with DC vaccines at the
Department of Cellular Therapy at Oslo University Hospital.
Dendritic cells (DCs) are the most potent antigen presenting cells of our immune
system. Their task is to take up, process and present antigens on their cell
surface, which enables them to activate antigen-specific T cells for maturation
and proliferation. This way T cells can recognize and eliminate antigen-bearing
tumor cells. Dendritic cells can also induce natural killer cells (NK cells) to
attack tumor cells. The team of Medigene Immunotherapies GmbH's scientists has
developed new, fast and efficient methods for generating dendritic cells ex-
vivo, which have relevant characteristics to activate both T cells and NK cells.
The DC vaccines are developed from autologous (patient-derived) precursor cells,
isolated from the patient's blood, and can be loaded with tumor-specific
antigens to treat different types of cancer. Medigene's DC vaccines are in
development for the treatment of minimal residual disease or use in combination
therapies.
Further audio-visual education about Medigene's DC-Vaccines at:
https://vimeo.com/123005832
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. The company is
developing highly innovative, complementary treatment platforms to target
various types and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized T cell-
based immunotherapies.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademark of Medigene AG. This trademark may be
owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor(at)medigene.com). We will then delete your address
from our distribution list.
--------------------------------------------------------------------------------
[1] Compassionate Use: Prescription of as-yet unapproved drugs in particularly
severe cases where there are no treatment alternatives
Press release English PDF:
http://hugin.info/132073/R/2011139/744470.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#2011139]
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 470141
Anzahl Zeichen: 7646
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clinical data of Medigene's dendritic cell (DC) vaccines in AML presented at CIMT conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
